Cytokinetics Inc (NASDAQ:CYTK)

CAPS Rating: 3 out of 5

A biopharmaceutical company, focused on developing small molecule therapeutics for the treatment of cardiovascular diseases and cancer.

Results 1 - 20 of 22 : 1 2 Next »

Recs

0
Member Avatar pchop123 (78.31) Submitted: 4/16/2014 2:38:20 PM : Outperform Start Price: $8.90 CYTK Score: +6.52

most likely to rebound significantly

Recs

0
Member Avatar TerryFool (21.60) Submitted: 4/15/2014 11:55:35 AM : Outperform Start Price: $8.94 CYTK Score: +4.14

buy now target price 11

Recs

0
Member Avatar TerryHoodSr (49.09) Submitted: 4/15/2014 9:52:51 AM : Outperform Start Price: $8.94 CYTK Score: +4.79

trade buy@ 9 TP 11

Recs

0
Member Avatar s2dbaker (90.96) Submitted: 1/10/2014 2:14:10 PM : Outperform Start Price: $9.22 CYTK Score: +1.75

This stock is on the move (hopefully that move is up).

Recs

0
Member Avatar SkepBioInvestor (88.92) Submitted: 11/30/2013 3:39:55 PM : Outperform Start Price: $6.52 CYTK Score: +43.09

Positive data from BENEFIT-ALS study in early 2014

Recs

0
Member Avatar PharmTeam (61.17) Submitted: 10/2/2013 1:29:06 PM : Outperform Start Price: $13.43 CYTK Score: -39.72

Cytokinetics has an AWESOME scientific platform, zero debt, and backing from Amgen. The stock was hit unfairly after ATOMIC trial failed, and I think if they can manage their cash burn then the science will shine through.

Recs

2
Member Avatar zzlangerhans (99.73) Submitted: 8/23/2013 10:05:26 AM : Outperform Start Price: $10.25 CYTK Score: -19.41

This is kind of a risky pick, in that I'm betting that the stock will rebound ahead of the presentation of ATOMIC-AHF results at the ESC conference in early September. That doesn't give me a lot of time to escape the pick ahead of data. Thus far. omecantiv has only been able to show improvement in physiologic parameters of cardiac function, and it would be quite a step forward if evidence is presented showing significant clinical benefit. I think there's a fairly good chance this won't be the case, so I'd prefer to be out before the data but there's a good chance I might not be able to close with a positive score. In that case, I'll squeeze my eyes shut and hold, with no real money on the line.

Recs

0
Member Avatar grahamfordummies (62.11) Submitted: 8/7/2013 7:49:09 PM : Outperform Start Price: $10.21 CYTK Score: -16.41

Low valuation ($299 million market cap) for two massive shots on goal. Omecamtiv in heart failure (with partner Amgen) and Tirasemtiv in ALS. 18 months of cash adequate to get through major milestones. Go big or go home.

Recs

0
Member Avatar rknapton (< 20) Submitted: 8/6/2013 7:30:28 PM : Underperform Start Price: $10.55 CYTK Score: +19.93

Short. Biotech. Low revenues. Massive stock issuance.

Recs

0
Member Avatar kaletbaldrich27 (< 20) Submitted: 7/10/2013 12:23:01 PM : Outperform Start Price: $13.30 CYTK Score: -41.52

Wouldn't be surprised if this stock hit the high teens by the end of the year. Cramer doesn't know what he's talking about.

Recs

0
Member Avatar RBuskey106 (63.41) Submitted: 3/21/2012 8:23:55 PM : Outperform Start Price: $7.14 CYTK Score: +0.74

Bio play

Recs

0
Member Avatar ReaperKK (< 20) Submitted: 2/13/2012 10:53:13 AM : Outperform Start Price: $7.08 CYTK Score: -3.65

Very specific product that will be promoted at an upcoming 4 conferences over the course of the next 2 months.

Recs

0
Member Avatar Thleter (68.65) Submitted: 5/24/2011 1:07:51 PM : Outperform Start Price: $8.10 CYTK Score: -23.71

Following tenmiles, I like what I saw when doing my initial research. Will be checking up on it more to see if I'm ready to throw down some real coin on it.

Recs

0
Member Avatar cheaply (22.66) Submitted: 2/9/2011 4:08:24 PM : Outperform Start Price: $11.16 CYTK Score: -56.32

The bottom I hope.

Recs

0
Member Avatar riponfool (57.12) Submitted: 4/28/2010 12:25:32 PM : Outperform Start Price: $19.01 CYTK Score: -106.40

it will hit @ $ 10.15

Recs

0
Member Avatar Nmendez10 (< 20) Submitted: 5/30/2009 1:05:16 PM : Outperform Start Price: $17.94 CYTK Score: -148.00

Their drug developments and clinical trials are promising. I think they will do better in the future.

Recs

0
Member Avatar PennyStockFool (29.44) Submitted: 12/4/2008 2:57:44 PM : Underperform Start Price: $12.06 CYTK Score: +143.94

This one looks like it could be heaed to the scrap heep....

Recs

0
Member Avatar snaphooks (< 20) Submitted: 9/9/2008 11:18:52 PM : Underperform Start Price: $27.72 CYTK Score: +120.92

guru short

Recs

0
Member Avatar doneb1 (< 20) Submitted: 2/3/2008 4:59:56 PM : Outperform Start Price: $22.38 CYTK Score: -97.00

if even i of its drugs being tested prove successful, it will be a good thing for terminal patients and investors

Recs

0
Member Avatar tharlow (64.51) Submitted: 8/21/2007 3:00:29 AM : Outperform Start Price: $28.62 CYTK Score: -102.42

Bargain basement. Giving it away at these prices.

Results 1 - 20 of 22 : 1 2 Next »

Featured Broker Partners


Advertisement